Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.970
+0.030 (1.02%)
At close: Jun 27, 2025, 4:00 PM
3.000
+0.030 (1.01%)
After-hours: Jun 27, 2025, 5:40 PM EDT
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
40.74M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GRCE News
- 2 days ago - Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 - GlobeNewsWire
- 4 days ago - Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update - GlobeNewsWire
- 14 days ago - Grace Therapeutics to Participate in the 2025 BIO International Conference - GlobeNewsWire
- 2 months ago - Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 - GlobeNewsWire
- 3 months ago - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - GlobeNewsWire
- 4 months ago - Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga